Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Non-Current Assets for 10 consecutive years, with $60.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 4.76% to $60.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.0 million through Dec 2025, down 4.76% year-over-year, with the annual reading at $60.0 million for FY2025, 4.76% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $60.0 million at Ultragenyx Pharmaceutical, up from $57.9 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $63.0 million in Q4 2024, with the low at $8.9 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $38.6 million, with a median of $38.1 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets surged 222.45% in 2021, then fell 4.76% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $20.6 million in 2021, then surged by 135.13% to $48.3 million in 2022, then rose by 19.34% to $57.7 million in 2023, then rose by 9.21% to $63.0 million in 2024, then dropped by 4.76% to $60.0 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $60.0 million, $57.9 million, and $60.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.